The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34(+) progenitor cells

Documenti analoghi

• Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring
  di: Oelschlaegel, Uta, et al.
  Pubblicazione: (2015)
• Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden
  di: Oelschlaegel, U, et al.
  Pubblicazione: (2016)
• Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial
  di: Sockel, Katja, et al.
  Pubblicazione: (2012)
• Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
  di: Prebet, Thomas, et al.
  Pubblicazione: (2017)
• Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion
  di: Duong, Vu H., et al.
  Pubblicazione: (2012)